Phase 3 Readout~month

Phase 3 Topline: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S

Name: Phase 3 Topline: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S
Start: 2027-03-17

March 17, 2027

Company: GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
Indication: Cough; Refractory Chronic Cough

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S — GSK Phase 3 Readout | BioSniper